Breathe Well Live Well
|
Govt announces plan to reduce health disparities
Fox News In between, they're more likely to suffer from a host of illnesses such as diabetes, heart disease, kidney disease and asthma. Part of the problem is access to care: Minorities make up more than half of the 50 million people who are uninsured, … |
View full post on asthma – Google News
|
N30 Pharmaceuticals Announces Publication of S-Nitrosoglutathione Reductase …
Marketwire (press release) The report focuses on the lead chemical series which generated N30 N6022, a first in class GSNOR inhibitor currently in Phase 1b/2a trials for the treatment of asthma. GSNOR breaks down S-nitrosoglutathione (GSNO), and as such is an important regulator … |
View full post on asthma – Google News
|
Verona Pharma announces positive results from mild asthma study
Trading Markets (press release) Verona Pharma plc, a biotechnology company, has completed a successful trial of higher doses of its lead respiratory drug, RPL554, in patients with mild asthma. The randomized, blinded trial, with placebo control, took place in Leiden, The Netherlands, … |
View full post on asthma – Google News
|
Targacept Announces Initiation of Phase 2 Studies of TC-6987 in Asthma and …
EON: Enhanced Online News (press release) TC-6987 demonstrated a potent anti-inflammatory response in a variety of preclinical studies conducted by Targacept, including models of asthma and diabetes … Targacept to begin phase 2 trials for its anti-inflammatory drug compound Targacept starts new trial for diabetes drug |
View full post on asthma – Google News
|
TARGACEPT : Announces Initiation of Phase 2 Studies of TC-6987 in Asthma and …
4-traders (press release) TC-6987 demonstrated a potent anti-inflammatory response in a variety of preclinical studies conducted by Targacept, including models of asthma and diabetes … |
View full post on asthma – Google News
|
Targacept Announces Initiation of Phase 2 Studies of TC-6987 in Asthma and …
Genetic Engineering News (press release) TC-6987 demonstrated a potent anti-inflammatory response in a variety of preclinical studies conducted by Targacept, including models of asthma and diabetes … |
View full post on asthma – Google News
|
Achieve Clinical Research Announces Asthma Research Studies in Birmingham, Alabama
PR.com (press release) "Through clinical research studies, we can strive to significantly build on data previously conducted on those currently diagnosed with asthma," says Hayes … |
View full post on asthma – Google News
|
Conway Announces $3.5 Million Settlement With Asthma Drug Manufacturer
LEX18 Lexington KY News Dey manufactures and markets the popular drugs Albuterol, Cromolyn Sodium, Ipratropium Bromide and other inhalation drugs used to treat asthma and chronic … |
View full post on asthma – Google News
|
ViroPharma Announces Six Upcoming Presentations of Cinryze(TM) (C1 Esterase …
MarketWatch (press release) There can be no assurance that that the data presented during the 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) … |
View full post on asthma – Google News
|
MedicNova Announces Poster Presentations at Annual Meeting of the American …
MarketWatch (press release) The presentations are related to MediciNova's development of MN-221 for potential utility in acute exacerbations of asthma or chronic obstructive pulmonary … |
View full post on asthma – Google News